Healthcare Economist August 15, 2023
While the Inflation Reduction Act (IRA) aims to lower the prices of pharmaceuticals, at the same time it exempts drugs treating rare diseases (i.e., orphan drugs) from drug price negotiation. However, this exemption is only valid if the orphan drugs has a single approved indication. Thus, a key question is how frequently orphan drugs are later developed for other indications. If so, IRA could could de-incentivize R&D investments in new indications for orphan drugs.
A new paper by Chambers et al. (2023) in JAMA Network Open FDA approval database between 2003 and 2022 to...
Today's Sponsors
Today's Sponsor